CClinicalTrials.gg
Sign In
Status unknownNCT01317186Updated Mar 17, 2011

The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease

An observational study in Metabolic Diseases and Chronic Kidney Disease, sponsored by Ankara Education and Research Hospital. Status unknown at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-03-17.

Sponsored by Ankara Education and Research Hospital · Observational

The sponsor has not verified this record recently (last verified Mar 2011), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Enrollment
100
Ages
18 Years to 65 Years
Sex
All
01

Study summary

In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.

02

Conditions studied

  • Metabolic Diseases
  • Chronic Kidney Disease

Keywords

  • FGF 23
  • ADMA
  • chronic kidney disease
  • Ca-P metabolism disorder
03

In context

Kidney Diseases

3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.

This study's planned enrollment of 100 is below the median of 192 across 1,033 observational studies indexed under Kidney Diseases.

Browse Kidney Diseases studies →

Lead sponsor

Ankara Education and Research Hospital is the lead sponsor of 13 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Stage 2-4 Non-diabetic Chronic Kidney Disease patients

Inclusion criteria

  • between ages of 18 - 65 years old
  • chronic kidney disease of stage 2-4

Exclusion criteria

Exclusion Criteria:

  • presence of diabetes mellitus or ischemic hearth disease
  • taking vitamin d therapy
05

Study design

Observational model
Cohort
Enrollment
100 participants (estimated)

Groups and cohorts

  • Group I

    Stage 2 Non-diabetic Chronic Kidney Disease

  • Group II

    Stage 3 Non-diabetic Chronic Kidney Disease

  • Group III

    Stage 4 Non-diabetic Chronic Kidney Disease

06

Study locations

1 of 1 sites recruiting
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 17, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT01317186
Lead sponsor
Ankara Education and Research Hospital
First posted
Mar 17, 2011
Start date
Mar 2011
Last update
Mar 17, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Kidney Diseases→

Other studies from this sponsor

Ankara Education and Research Hospital

Start the discussion